(NOVO-B) Novo Nordisk - Ratings and Ratios
Diabetes, Obesity, Insulin, Hormone, Rare Disorder Medications
NOVO-B EPS (Earnings per Share)
NOVO-B Revenue
Description: NOVO-B Novo Nordisk
Novo Nordisk A/S is a leading pharmaceutical company with a strong presence in the global market, operating in two main segments: Diabetes and Obesity Care, and Rare Disease. The companys product portfolio includes a range of diabetes and obesity treatments, as well as therapies for rare blood disorders and endocrine disorders.
The companys Diabetes and Obesity Care segment is a significant contributor to its revenue, with products such as insulin pens and smart insulin pens, as well as Dose Check, an insulin dose guidance application. Novo Nordisks focus on innovation is evident in its collaborations with organizations such as UNICEF and Valo Health, Inc., aimed at tackling childhood obesity and developing novel drug programs for cardiometabolic diseases.
From a financial perspective, Novo Nordisks market capitalization stands at approximately 191.6 billion DKK, with a forward P/E ratio of 16.64, indicating a relatively attractive valuation. The companys return on equity (RoE) is remarkably high at 81.24%, suggesting strong profitability. Additionally, the companys dividend yield is an attractive feature for income-seeking investors.
Some key performance indicators (KPIs) to monitor for Novo Nordisk include revenue growth, particularly in its Diabetes and Obesity Care segment, as well as the success of its pipeline products and collaborations. Other important metrics include the companys operating margin, which is likely to be influenced by its pricing power and competition in the market. The companys ability to maintain its high RoE and generate strong cash flows will also be crucial in driving its long-term growth and returns to shareholders.
In terms of growth prospects, Novo Nordisks focus on emerging therapy areas, such as cardiometabolic diseases, and its innovative products, such as smart insulin pens, are likely to drive future growth. The companys strong presence in the global market, combined with its commitment to research and development, positions it well for long-term success.
NOVO-B Stock Overview
| Market Cap in USD | 240,349m |
| Sub-Industry | Biotechnology |
| IPO / Inception |
NOVO-B Stock Ratings
| Growth Rating | 1.43% |
| Fundamental | 77.1% |
| Dividend Rating | 63.6% |
| Return 12m vs S&P 500 | -65.2% |
| Analyst Rating | - |
NOVO-B Dividends
| Dividend Yield 12m | 2.52% |
| Yield on Cost 5y | 6.11% |
| Annual Growth 5y | 35.72% |
| Payout Consistency | 74.9% |
| Payout Ratio | 46.7% |
NOVO-B Growth Ratios
| Growth Correlation 3m | -83.2% |
| Growth Correlation 12m | -94.5% |
| Growth Correlation 5y | 81% |
| CAGR 5y | 13.11% |
| CAGR/Max DD 5y | 0.18 |
| Sharpe Ratio 12m | -1.19 |
| Alpha | -73.03 |
| Beta | 0.757 |
| Volatility | 62.72% |
| Current Volume | 4523k |
| Average Volume 20d | 7565.5k |
| Stop Loss | 344.2 (-4.1%) |
| Signal | -1.29 |
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (111.07b TTM) > 0 and > 6% of Revenue (6% = 18.72b TTM) |
| FCFTA 0.13 (>2.0%) and ΔFCFTA -5.02pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -14.37% (prev -4.03%; Δ -10.33pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.25 (>3.0%) and CFO 121.53b > Net Income 111.07b (YES >=105%, WARN >=100%) |
| Net Debt (80.83b) to EBITDA (38.88b) ratio: 2.08 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.78 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (4.44b) change vs 12m ago -0.54% (target <= -2.0% for YES) |
| Gross Margin 83.95% (prev 84.53%; Δ -0.58pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 73.26% (prev 69.85%; Δ 3.42pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 2.97 (EBITDA TTM 38.88b / Interest Expense TTM 11.57b) >= 6 (WARN >= 3) |
Altman Z'' 1.59
| (A) -0.09 = (Total Current Assets 162.71b - Total Current Liabilities 207.52b) / Total Assets 482.15b |
| (B) 0.34 = Retained Earnings (Balance) 164.45b / Total Assets 482.15b |
| (C) 0.08 = EBIT TTM 34.38b / Avg Total Assets 425.77b |
| (D) 0.52 = Book Value of Equity 164.45b / Total Liabilities 314.09b |
| Total Rating: 1.59 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 77.06
| 1. Piotroski 5.50pt = 0.50 |
| 2. FCF Yield 3.83% = 1.92 |
| 3. FCF Margin 19.87% = 4.97 |
| 4. Debt/Equity 0.59 = 2.33 |
| 5. Debt/Ebitda 2.55 = -1.05 |
| 6. ROIC - WACC 3.09% = 3.86 |
| 7. RoE 77.86% = 2.50 |
| 8. Rev. Trend 96.27% = 4.81 |
| 9. Rev. CAGR 20.94% = 2.50 |
| 10. EPS Trend 88.73% = 2.22 |
| 11. EPS CAGR 25.73% = 2.50 |
What is the price of NOVO-B shares?
Over the past week, the price has changed by +0.76%, over one month by -19.54%, over three months by -19.98% and over the past year by -59.10%.
Is Novo Nordisk a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of NOVO-B is around 298.57 DKK . This means that NOVO-B is currently overvalued and has a potential downside of -16.79%.
Is NOVO-B a buy, sell or hold?
What are the forecasts/targets for the NOVO-B price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 497.9 | 38.8% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 332.9 | -7.2% |
NOVO-B Fundamental Data Overview
Market Cap DKK = 1536.76b (1536.76b DKK * 1.0 DKK.DKK)
CCE Cash And Equivalents = 18.43b DKK (Cash only, last quarter)
P/E Trailing = 13.8617
P/E Forward = 14.0449
P/S = 4.9265
P/B = 9.1874
P/EG = 1.5996
Beta = 0.274
Revenue TTM = 311.94b DKK
EBIT TTM = 34.38b DKK
EBITDA TTM = 38.88b DKK
Long Term Debt = 87.31b DKK (from longTermDebt, last quarter)
Short Term Debt = 11.96b DKK (from shortLongTermDebt, last quarter)
Debt = 99.27b DKK (Calculated: Short Term 11.96b + Long Term 87.31b)
Net Debt = 80.83b DKK (from netDebt column, last quarter)
Enterprise Value = 1617.59b DKK (1536.76b + Debt 99.27b - CCE 18.43b)
Interest Coverage Ratio = 2.97 (Ebit TTM 34.38b / Interest Expense TTM 11.57b)
FCF Yield = 3.83% (FCF TTM 61.99b / Enterprise Value 1617.59b)
FCF Margin = 19.87% (FCF TTM 61.99b / Revenue TTM 311.94b)
Net Margin = 35.61% (Net Income TTM 111.07b / Revenue TTM 311.94b)
Gross Margin = 83.95% ((Revenue TTM 311.94b - Cost of Revenue TTM 50.07b) / Revenue TTM)
Tobins Q-Ratio = 9.84 (Enterprise Value 1617.59b / Book Value Of Equity 164.45b)
Interest Expense / Debt = 4.99% (Interest Expense 4.96b / Debt 99.27b)
Taxrate = 20.60% (from yearly Tax Provision: 26.20b / 127.19b)
NOPAT = 27.30b (EBIT 34.38b * (1 - 20.60%))
Current Ratio = 0.78 (Total Current Assets 162.71b / Total Current Liabilities 207.52b)
Debt / Equity = 0.59 (Debt 99.27b / last Quarter total Stockholder Equity 168.07b)
Debt / EBITDA = 2.55 (Net Debt 80.83b / EBITDA 38.88b)
Debt / FCF = 1.60 (Debt 99.27b / FCF TTM 61.99b)
Total Stockholder Equity = 142.65b (last 4 quarters mean)
RoA = 23.04% (Net Income 111.07b, Total Assets 482.15b )
RoE = 77.86% (Net Income TTM 111.07b / Total Stockholder Equity 142.65b)
RoCE = 14.95% (Ebit 34.38b / (Equity 142.65b + L.T.Debt 87.31b))
RoIC = 11.60% (NOPAT 27.30b / Invested Capital 235.40b)
WACC = 8.51% (E(1536.76b)/V(1636.03b) * Re(8.80%)) + (D(99.27b)/V(1636.03b) * Rd(4.99%) * (1-Tc(0.21)))
Shares Correlation 5-Years: -90.0 | Cagr: -1.08%
Discount Rate = 8.80% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 76.98% ; FCFE base≈63.60b ; Y1≈69.73b ; Y5≈88.93b
Fair Price DCF = 399.5 (DCF Value 1345.60b / Shares Outstanding 3.37b; 5y FCF grow 11.02% → 3.0% )
Revenue Correlation: 96.27 | Revenue CAGR: 20.94%
Rev Growth-of-Growth: -6.86
EPS Correlation: 88.73 | EPS CAGR: 25.73%
EPS Growth-of-Growth: -13.31